Appili Therapeutics (Appili Therapeutics) FCF Margin % : 53.09% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Appili Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $0.19 Mil. Appili Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.36 Mil. Therefore, Appili Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 53.09%.

As of today, Appili Therapeutics's current FCF Yield % is -73.53%.

The historical rank and industry rank for Appili Therapeutics's FCF Margin % or its related term are showing as below:

APLIF' s FCF Margin % Range Over the Past 10 Years
Min: -3024.25 Med: -2141.21 Max: -275.85
Current: -275.85

During the past 6 years, the highest FCF Margin % of Appili Therapeutics was -275.85%. The lowest was -3024.25%. And the median was -2141.21%.

APLIF's FCF Margin % is ranked worse than
58.51% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs APLIF: -275.85

Appili Therapeutics FCF Margin % Historical Data

The historical data trend for Appili Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics FCF Margin % Chart

Appili Therapeutics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-2,134.97

-1,371.43

-3,025.41

Appili Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-331.97	-	-70.28	53.09

Competitive Comparison of Appili Therapeutics's FCF Margin %

For the Biotechnology subindustry, Appili Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's FCF Margin % falls into.

Appili Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Appili Therapeutics's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-7.382	/	0.244
	=	-3,025.41 %

Appili Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0.189	/	0.356
	=	53.09 %

Appili Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Appili Therapeutics (Appili Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

APLI:Canada

Address

1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8

Website

https://www.appilitherapeutics.com

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.